Clinical Trial Update: Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating idelalisib plus rituximab for previously untreated follicular lymphoma and small lymphocytic lymphoma was terminated; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-18